Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Nektar And Bristol-Myers Squibb's Deal Could Be An Opportunity For NewLink

2018-02-20 seekingalpha
Nektar and BMY's PIVOT-02 trial provided proof of concept for the synergistic action between PD-1 inhibition and T-Cell proliferation by Nektar’s NKTR-214 with tolerable safety profile. (86-0)

Cancer data: a dive into the depths - European Biotechnology

2018-02-16 european-biotechnology
As Big Data analytics begin to inspire medical decisionmaking, companies and scientists have gone to war over access to data derived from patient biopsies. Cancer profiling is a seminal situation. While some companies are seeking to profit from approaches to advanced mutation analysis, researchers are vociferous in demanding open access to proprietary data­bases behind company firewalls. (9-0)

Updating My Bullish Views On Vertex Pharmaceuticals

2018-02-15 seekingalpha
VRTX is an emerging though large-cap biotech with a growing portfolio of drugs for cystic fibrosis. (15-0)

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

2018-02-15 in.reuters
FRANKFURT (Reuters) - Merck KGaA and Pfizer’s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

2018-02-15 reuters
FRANKFURT (Reuters) - Merck KGaA and Pfizer’s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

2018-02-15 seekingalpha
Today we will focus on Achaogen (AKAO), which got a slight boost after Tetraphase Pharma’s (TTPH) drug failed to beat ertapenem in a late-stage cUTI study. (426-3)

Merck & Co.’s Revenues in 4Q17

2018-02-15 editors.aws.marketrealist
Headquartered in New Jersey, Merck & Co.’s (MRK) portfolio comprises its Human Pharmaceutical Products and Animal Health Products segments. Merck & Co. reported revenue growth of 3.0% to ~$10.4 billion in 4Q17 compared to $10.1 billion in revenues in 4Q16. 

How Did Vertex Pharmaceuticals Perform in 4Q17 and 2017?

2018-02-05 editors.aws.marketrealist
In 4Q17, Vertex Pharmaceuticals (VRTX) generated revenues of $622 million, which reflected ~36% growth on a year-over-year (or YoY) basis and ~20% growth on a quarter-over-quarter basis. In fiscal 2017, Vertex Pharmaceuticals reported revenues of $2.2 million, which is ~29% growth on a YoY basis. (1-0)

Merck's consumer health sale at risk as Nestle bows out: Report

2018-02-02 cnbc
The sale of Merck KGaA's consumer health unit has been thrown off track after Nestle has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters.

Exclusive: Merck's consumer health sale at risk as Nestle bows out - sources

2018-02-02 reuters
LONDON/FRANKFURT (Reuters) - The sale of Merck KGaA’s (MRCG.DE) consumer health unit has been thrown off track after Nestle (NESN.S) has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters.

Exclusive: Merck's consumer health sale at risk as Nestle bows out - sources - Channel NewsAsia

2018-02-02 channelnewsasia
The sale of Merck KGaA's consumer health unit has been thrown off track after Nestle has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters.

Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

2018-02-01 zacks
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported fourth-quarter 2017 earnings per share of 61 cents, which beat the Zacks Consensus Estimate of 58 cents and came ahead of the year-ago earnings of 35 cents. Strong product revenues led to higher profits in the quarter and lower operating expense ratio year over year. (7-0)

Pfizer's (PFE) CEO Ian Read on Q4 2017 Results - Earnings Call Transcript

2018-01-31 seekingalpha
Good day, everyone, and welcome to Pfizer's Fourth Quarter 2017 Earnings Conference Call. Today's call is being recorded. (6-0)

Exclusive: J&J out of race for Pfizer's $20 billion consumer unit as deadline looms

2018-01-25 in.reuters
LONDON/NEW YORK/FRANKFURT (Reuters) - Johnson & Johnson has pulled out of the race to buy Pfizer’s consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids, according to sources familiar with the matter. (12-0)

Exclusive: J&J out of race for Pfizer's $20 bln consumer unit as deadline looms

2018-01-25 reuters
LONDON/NEW YORK/FRANKFURT (Reuters) - Johnson & Johnson (JNJ.N) has pulled out of the race to buy Pfizer’s (PFE.N) consumer health business, leaving GlaxoSmithKline (GSK.L) and Reckitt Benckiser (RB.L) among those preparing bids, according to sources familiar with the matter. (12-0)


CUSIP: 004741844